Muthiah Vaduganathan, MD
Cardiovascular Disease · Boston, MANPI 1023370467
Payments from drug & device makers
Across 488 payments — averaging $3139.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Diagnostics International Ltd$468K
- American Regent$164K
- AstraZeneca$120K
- Bayer$94K
- Lexicon Pharmaceuticals, Inc.$93K
- Boehringer Ingelheim$73K
- plus $520K from 29 others
Across 5 payments — averaging $3385.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$13K
- Novartis$2K
- Sanofi-aventis U.S. LLC$1K
- Boehringer Ingelheim International GmbH$80
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Diagnostics International Ltd | 25 | $468,014 |
| American Regent | 8 | $164,131 |
| AstraZeneca | 81 | $120,366 |
| Bayer | 77 | $94,370 |
| Lexicon Pharmaceuticals, Inc. | 12 | $92,504 |
| Boehringer Ingelheim | 51 | $72,760 |
| Amgen | 32 | $68,064 |
| Boehringer Ingelheim International GmbH | 25 | $63,617 |
| Occlutech US LLC | 1 | $54,000 |
| Novo Nordisk AS | 11 | $46,799 |
| Novo Nordisk | 17 | $38,090 |
| Eli Lilly | 16 | $38,048 |
| Astrazeneca UK Limited | 33 | $34,383 |
| Pharmacosmos Therapeutics Inc. | 4 | $25,409 |
| Sanofi-aventis U.S. LLC | 6 | $21,955 |
| Lilly USA, LLC | 7 | $20,400 |
| Merck | 22 | $17,731 |
| Recordati_rare_diseases_inc. | 7 | $15,314 |
| Esperion Therapeutics, Inc. | 6 | $13,907 |
| E.r. Squibb & Sons, L.L.C. | 8 | $11,144 |
| Chiesi USA, Inc. | 2 | $8,797 |
| Novartis | 9 | $8,511 |
| Astrazeneca AB | 4 | $7,804 |
| Alnylam Pharmaceuticals Inc. | 4 | $5,367 |
| Baxter Healthcare | 2 | $4,971 |
| Roche Diagnostics Corporation | 2 | $4,839 |
| Vifor Pharma, Inc. | 7 | $3,721 |
| Idorsia Pharmaceuticals US Inc | 1 | $3,540 |
| Boehringer Ingelheim Del Ecuador Cia. Ltda. | 1 | $2,320 |
| Chugai Pharmaceutical Co., Ltd. | 1 | $805 |
| Impulse Dynamics (USA) Inc. | 2 | $165 |
| Sandoz | 1 | $125 |
| Edwards Lifesciences | 1 | $91 |
| Endotronix, Inc. | 1 | $50 |
| Boston Scientific | 1 | $39 |
How this compares
$1,532,151 in reported general payments places this provider in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Boston
- Marc SabatineBoston$31.2M
- Stephen WiviottBoston$29.2M
- David MorrowBoston$19M
- Scott SolomonBoston$16.2M
- Paul RidkerBoston$16.2M
- Mohit JainBoston$13M
- Calum MacraeBoston$11.4M
- Benjamin SciricaBoston$11.3M
- Robert GiuglianoBoston$10.5M
- Erin BohulaBoston$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.